Floatz logo

Zidesamtinib

Locally Advanced Solid Tumor

Nuvalent Inc.Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

53 Active assets in the Locally Advanced Solid Tumor cohort.

Asset / SponsorPhaseRating
vc004
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3B
Nivolumab
Mohammed Milhem
Phase 2B
Eloxatin
Parabilis Medicines, Inc.
Phase 2B
TRASTUZUMAB
Aiping Zhou
Phase 2B
Cetrelimab
University Medical Center Groningen
Phase 2CCC

View all 50 →

Same molecule, other indications

Zidesamtinib is also rated in:

Metastatic Solid TumorDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →